Journals / Erciyes Tıp Dergisi / 2010 / Cilt: 32 - Sayı: 1

Coagulopaty due to cefoperazone/sulbactam in a patient with chronic renal failure : Case report

Kronik böbrek yetmezliği olan bir hastada sefoperazon/sulbaktam kullanımına bağlı gelişen koagülopati : Olgu sunumu

Pages
45–48
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We report that in a patient with peritoneal dialysis, bleeding by inducing hypoprotrombinemia developing during cefoperazone/sulbactam therapy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Continuous ambulatory peritoneal dialysis is one of renal replacement treatment in patients with end-stage kidney disease.
📊
Key Findings & Data:Peritonitis is a serious problem in peritoneal dialysis patients that leads to hospitalisation and increased mortality.
💡
Conclusion & Impact:We report that in a patient with peritoneal dialysis, bleeding by inducing hypoprotrombinemia developing during cefoperazone/sulbactam therapy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Continuous ambulatory peritoneal dialysis is one of renal replacement treatment in patients with end-stage kidney disease. Peritonitis is a serious problem in peritoneal dialysis patients that leads to hospitalisation and increased mortality. In treatment of peritoneal dialysis- associated peritonitis, broad spectrum antibiotics have been used according to potential dominant microorganism. With the extended spectrum and a remarkably safe, third generation cephalosporins are used frequently in clinics. Cefoperazone/sulbactam, which is one of the third generation cephalosporins, causes bleeding because of it induces hypoprothrombinemia. We report that in a patient with peritoneal dialysis, bleeding by inducing hypoprotrombinemia developing during cefoperazone/sulbactam therapy.

Özet

Son dönem böbrek yetmezliği olan hastalarda sürekli ayaktan periton diyalizi, böbrek yerine koyma tedavisi seçeneklerinden birisidir. Peritonit, periton diyalizi uygulayan hastalarda, hastaneye yatırılmaya ve artmış mortaliteye neden olması açısından ciddi bir klinik durumdur. Peritonitin tedavisinde olası etken mikroorganizmaya göre antibiyotik seçilmektedir. Geniş etki spektrumlu ve güvenilir antibiyotikler olan sefalosporinler klinikte oldukça sık kullanılmaktadır. Sefoperazon/sulbaktam kullanımı sırasında hastalarda hipoprotrombinemiye ikincil ciddi kanamalar meydana gelebilmektedir. Bu vakayı, sıklıkla atlanan bu klinik duruma dikkat çekmek için sunduk.

🔖

Cite This Article

ÜNAL, A., TOKGÖZ, B., OYMAK, O., UTAŞ, C., SİPAHİOĞLU, M. H., KORKMAZ, A. E., KORKMAZ, Z. (2022). Coagulopaty due to cefoperazone/sulbactam in a patient with chronic renal failure : Case report. Erciyes Tıp Dergisi, Cilt: 32 - Sayı: 1, 45–48. https://ajindex.com/articles/502543

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Neu HC. Third generation cephalosporins: safety profiles after 10 years of clinical use. J Clin Pharmacol 1990; 30:396-403
  2. Fekety FR. Safety of parenteral third-generation cephalosporins. Am J Med 1990;88:38S-44S
  3. Strippoli GF, Tong A, Johnson D, Schena FP, Craig JC. Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients. Cochrane Database Syst Rev 2004;(4):CD004679
  4. Gokal R. Techniques, indications and complications of peritoneal dialysis. In: Massry SG, Glassock RJ, editors. Textbook of Nephrology. Lippincott Williams & Wilkins; Philadelphia: 2001. p.1532-1542
  5. Wong RS, Cheng G, Chan NP, Wong WS, NG MH. Use of cefoperazone still needs a caution for bleeding from induced vitamin K deficiency. Am J Hematol 2006; 81:76
  6. Alagozlu H, Cindoruk M, Unal S. Severe INR elevation in a patient with choledocholithiasis receiving cefoperazone. Clin Drug Investig 2006; 26:481-484
  7. Shenkenberg TD, Mackowiak PA, Smith JW. Coagulopathy and hemorrhage associated with cefoperazone therapy in a patient with renal failure. South Med J 1985; 78:488-489
  8. Mann KG, Whelihan MF, Butenas S, Orfeo T. Citrate anticoagulation and the dynamics of thrombin generation. J Thromb Haemost 2007;5:2055-2061.